Page 137 - 南京医科大学学报自然科学版

第44卷第3期 陈 玲，张 群，何梦钰，等. 间质性肺疾病合并肺癌的机制及治疗进展［J］.
2024年3月 南京医科大学学报（自然科学版），2024，44（3）：423-428 ·427 ·

fibrosis［J］. J Cell Mol Med，2002，6（2）：215-222 ［J］. BMC Cancer，2019，19（1）：163
［9］ HATA A，NAKAJIMA T，MATSUSAKA K，et al. Genetic ［21］ KENMOTSU H，NAITO T，KIMURA M，et al. The risk of
alterations in squamous cell lung cancer associated with cytotoxic chemotherapy⁃related exacerbation of interstitial
idiopathic pulmonary fibrosis［J］. Int J Cancer，2021，148 lung disease with lung cancer［J］. J Thorac Oncol，2011，6
（12）：3008-3018 （7）：1242-1246
［10］ MOSS B J，RYTER S W，ROSAS I O. Pathogenic mecha⁃ ［22］ MINEGISHI Y，GEMMA A，HOMMA S，et al. Acute exa⁃
nisms underlying idiopathic pulmonary fibrosis［J］. Annu cerbation of idiopathic interstitial pneumonias related to
Rev Pathol Mech Dis，2022，17：515-546 chemotherapy for lung cancer：nationwide surveillance in
［11］ PAKSHIR P，NOSKOVICOVA N，LODYGA M，et al. The Japan［J］. ERJ Open Res，2020，6（2）：184-219
myofibroblast at a glance［J］. J Cell Sci，2020，133（13）： ［23］ LONG K，SURESH K. Pulmonary toxicity of systemic lung
jcs227900 cancer therapy［J］. Respirology，2020，25（Suppl 2）：72-79
［12］FIORI M E，DI FRANCO S，VILLANOVA L，et al. Cancer ［24］ MIN J H，LEE H Y，LIM H，et al. Drug⁃induced intersti⁃
⁃associated fibroblasts as abettors of tumor progression at tial lung disease in tyrosine kinase inhibitor therapy for
the crossroads of EMT and therapy resistance［J］. Mol non⁃small cell lung cancer：a review on current insight［J］.
Cancer，2019，18（1）：70 Cancer Chemother Pharmacol，2011，68（5）：1099-1109
［13］ PIERSMA B，HAYWARD M K，WEAVER V M. Fibrosis ［25］ OHMORI T，YAMAOKA T，ANDO K，et al. Molecular
and cancer：a strained relationship［J］. Biochim Biophys and clinical features of EGFR⁃TKI⁃associated lung injury
Acta BBA Rev Cancer，2020，1873（2）：188356 ［J］. Int J Mol Sci，2021，22（2）：792
［14］ OHSAWA M，TSUTANI Y，FUJIWARA M，et al. Predict⁃ ［26］ JIA W X，GAO Q Q，WANG M，et al. Overlap time is an
ing severe postoperative complication in patients with independent risk factor of radiation pneumonitis for pa⁃
lung cancer and interstitial pneumonia［J］. Ann Thorac tients treated with simultaneous EGFR⁃TKI and thoracic
Surg，2020，109（4）：1054-1060 radiotherapy［J］. Radiat Oncol，2021，16（1）：41
［15］ HAO X H，HAO J Q，CHEN C，et al. Risk factors for ［27］ ZHANG M，FAN Y，NIE L G，et al. Clinical outcomes of
acute exacerbation of interstitial lung disease following immune checkpoint inhibitor therapy in patients with ad⁃
lung cancer resection：a systematic review and meta⁃analy⁃ vanced non⁃small cell lung cancer and preexisting inter⁃
sis［J］. Interact Cardiovasc Thorac Surg，2022，34（5）： stitial lung diseases：a systematic review and meta⁃analy⁃
744-752 sis［J］. Chest，2022，161（6）：1675-1686
［16］ OZAWA Y，SHIBAMOTO Y，HIROSHIMA M，et al. Pre⁃ ［28］ MATSUMOTO K，SHIROYAMA T，KUGE T，et al. Im⁃
operative CT findings for predicting acute exacerbation of pact of treatment line on risks and benefits of immune
interstitial pneumonia after lung cancer surgery：a multi⁃ checkpoint inhibitor in patients with advanced non⁃small
center case ⁃ control study［J］. AJR Am J Roentgenol， cell lung cancer and interstitial lung disease：a systematic
2021，217（4）：859-869 review and meta ⁃ analysis of cohort studies［J］. Transl
［17］ ZHAO J，YORKE E D，LI L，et al. Simple factors associated Lung Cancer Res，2022，11（9）：1835-1846
with radiation ⁃ induced lung toxicity after stereotactic ［29］ KIM S，LIM J U. Immune checkpoint inhibitor⁃related in⁃
body radiation therapy of the thorax：a pooled analysis of terstitial lung disease in patients with advanced non⁃small
88 studies［J］. Int J Radiat Oncol Biol Phys，2016，95 cell lung cancer：systematic review of characteristics，inci⁃
（5）：1357-1366 dence，risk factors，and management［J］. J Thorac Dis，
［18］ GLICK D，LYEN S，KANDEL S，et al. Impact of pretreat⁃ 2022，14（5）：1684⁃1695
ment interstitial lung disease on radiation pneumonitis ［30］ FRANGOGIANNIS N. Transforming growth factor⁃β in tis⁃
and survival in patients treated with lung stereotactic sue fibrosis［J］. J Exp Med，2020，217（3）：20190103
body radiation therapy（SBRT）［J］. Clin Lung Cancer， ［31］ LIU S J，REN J，TEN DIJKE P. Targeting TGFβ signal
2018，19（2）：219-226 transduction for cancer therapy［J］. Signal Transduct Tar⁃
［19］ KONG F S，MOISEENKO V，ZHAO J，et al. Organs at get Ther，2021，6（1）：8
risk considerations for thoracic stereotactic body radiation ［32］ NACCACHE J M，GIBIOT Q，MONNET I，et al. Lung can⁃
therapy：what is safe for lung parenchyma?［J］. Int J Radiat cer and interstitial lung disease：a literature review［J］. J
Oncol Biol Phys，2021，110（1）：172-187 Thorac Dis，2018，10（6）：3829-3844
［20］ SHIRASAWA M，FUKUI T，KUSUHARA S，et al. Efficacy ［33］ ANTAR S A，SALEH M A，AL⁃KARMALAWY A A. In⁃
and risk of cytotoxic chemotherapy in extensive disease⁃ vestigating the possible mechanisms of pirfenidone to be
small cell lung cancer patients with interstitial pneumonia targeted as a promising anti⁃inflammatory，anti⁃fibrotic，